cis-4-(tert-Butyl)cyclohexanamine hydrochloride | 91342-35-7

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: cis-4-(tert-Butyl)cyclohexanamine hydrochloride
• 英文别名: 4-tert-butylcyclohexan-1-amine;hydrochloride
• CAS: 91342-35-7
• 化学式: C₁₀H₂₁N*ClH
• 分子量: 191.744
• InChiKey: GKZRLLGEYNJZDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.97
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  26
• 氢给体数：
  2
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  methyl 2-(6-(1-bromo-4-methylpentyl)-4'-(trifluoromethyl)biphenyl-3-yl)acetate 、 cis-4-(tert-Butyl)cyclohexanamine hydrochloride 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成
  参考文献：
  名称：

  Discovery of 4-aminomethylphenylacetic acids as γ-secretase modulators via a scaffold design approach

  摘要：

  Starting from literature examples of nonsteroidal anti-inflammatory drugs (NSAIDs)-type carboxylic acid gamma-secretase modulators (GSMs) and using a scaffold design approach, we identified 4-aminomethylphenylacetic acid 4 with a desirable gamma-secretase modulation profile. Scaffold optimization led to the discovery of a novel chemical series, represented by 6b, having improved brain penetration. Further SAR studies provided analog 6q that exhibited a good pharmacological profile. Oral administration of 6q significantly reduced brain A beta 42 levels in mice and rats. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.047

文献信息

• Urea Glucokinase Activators
  申请人：Lau Jesper

  公开号：US20090105482A1

  公开（公告）日：2009-04-23

  The invention provides a compound of general formula (I) wherein the substituents are defined further in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了一种具有一般式(I)的化合物，其中取代基在申请书中进一步定义，以及在所附的实施例中进一步描述的本发明的其他实施例。本发明还提供了使用该化合物制备药物治疗各种疾病的用途，例如治疗2型糖尿病。
• 3H-Imidazo [4, 5-B] Pyridine- 6 -Carboxamides As Anti-Inflammatory Agents
  申请人：Pfau Roland

  公开号：US20120115902A1

  公开（公告）日：2012-05-10

  There are provided compounds of formula (I), wherein R 1 , R 6 , R 8 , Q 2 , Q 3 , Q 3a , Q 4 , L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family is desired and/or required, and particularly in the treatment of inflammation and/or cancer.

  提供了公式（I）的化合物，其中R1、R6、R8、Q2、Q3、Q3a、Q4、L和A的含义在说明中给出，并且其药学上可接受的盐，在希望和/或需要抑制MAPEG家族成员活性的疾病治疗中非常有用，特别是在炎症和/或癌症治疗中。
• Urea glucokinase activators
  申请人：NOVO NORDISK A/S

  公开号：EP2377856A1

  公开（公告）日：2011-10-19

  The invention provides a compound of general formula (1) wherein the substituents are defined futher in the application, as well as further embodiments hereof described in the attached embodiments. The present invention also provides use of the compounds of the invention for preparation of a medicament for the treatment of various diseases, e.g. for the treatment of type 2 diabetes.

  本发明提供了通式（1）的化合物 其中取代基在本申请中进一步定义，以及在所附实施例中描述的本发明的进一步实施例。 本发明还提供了本发明化合物用于制备治疗各种疾病的药物的用途，例如用于治疗 2 型糖尿病。
• UREA GLUCOKINASE ACTIVATORS
  申请人：Novo Nordisk A/S

  公开号：EP1904467A1

  公开（公告）日：2008-04-02
• 3H-IMIDAZO[4,5-b]PYRIDINE-6-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2350073B1

  公开（公告）日：2014-11-12